


“A lot is currently happening at Lipum and R&D work involves many experts in different areas. For us, proactive and committed IPR skills are extremely valuable. Valea is constantly involved in the team and offers strategic guidance.”

– Einar Pontén



Lipum, developing biological anti-inflammatory drugs

Lipum AB is a biotech company dedicated to developing safe, novel and effective anti-inflammatory drugs that will fulfil an important medical need for patients suffering from chronic inflammatory diseases, such as severe juvenile idiopathic arthritis (JIA) in children, rheumatoid arthritis (RA) in adults and inflammatory bowel disease (IBD).

Olle Hernell, Susanne Lindquist and Lennart Lundberg founded Lipum AB in 2010. The company's registered office and preclinical research activities are in Umeå, Sweden.

RA is an autoimmune disease affecting about 1% of the world's population and big pharma's RA drugs have traditionally been among the most lucrative blockbuster drugs. Still, many patients fail first and second line treatments. Thus, research is currently focused on finding third line treatments with other biological drugs, such as TNF α inhibitors, other cytokine inhibitors and a class of small molecules known as Janus Kinase (JAK) inhibitors. However, many patients do not get an adequate response with these treatments, therefore leaving a large unmet medical need for more effective and/or safer treatment in fourth line treatment, where options are few.

Lipum aims to fill this gap and has identified a novel target for treating chronic inflammatory diseases. The target is a protein denoted bile salt-stimulated lipase (BSSL). Lipum's therapeutic approach is to develop an antibody that blocks the function of BSSL, thereby inhibiting the inflammatory process.

A non-clinical proof of concept has been established and Lipum has developed a humanized monoclonal antibody to enter non-clinical and clinical development. Following this, Lipum aims to bring its lead human antibody to a clinical proof of concept in a clinical Phase IIa study before executing a strategic partnership.

To further strengthen Lipum's competitive position, a strong asset portfolio has been built by strategic Life Cycle Management of its IP portfolio, applying for orphan drug designation (JIA) and creating a pediatric investigational plan.

Choosing a Tier-1 company, and in particular Valea as their IP partner, is a strategic move in this process and testimony that Lipum considers pro-active IP an essential ingredient for their future success in the market and their imminent success in attracting both early partnering and a strategic partnership.



ANNIKA UNGE
European Patent Attorney
Authorised Patent Attorney (SE)
Manager Team LifeTech & Chemistry
Partner

LIPUM

Founded: 2010

Products: A therapeutic antibody directed towards BSSL – a novel target for treatment of autoimmune chronic inflammatory diseases.

Market: They aim to eliminate or alleviate painful symptoms and improve the quality of life for millions of patients suffering.